Alvotech Partners with Lotus Pharmaceutical for U.S. and Asian Biosimilar Expansion — Alvotech

Event summary

Alvotech licenses AVT34 (biosimilar to durvalumab) and AVT87 (biosimilar to emicizumab) to Lotus Pharmaceutical for U.S. and Asian markets.
Deal includes up to $150M in upfront and milestone payments, plus ongoing supply revenues.
Alvotech retains U.S. commercialization rights alongside Lotus, while Lotus gets exclusive rights in eight Asian markets.
AVT34 targets AstraZeneca’s $6.1B durvalumab, AVT87 targets Roche’s $5.8B emicizumab.
Alvotech will handle product development and regulatory approvals in the U.S.

The big picture

This deal marks Alvotech’s first direct U.S. commercialization effort, expanding its reach beyond Europe and Asia. The partnership with Lotus Pharmaceutical strengthens Alvotech’s position in biosimilars, targeting high-revenue oncology and rare disease markets. The agreement underscores the growing trend of strategic alliances in biotech to navigate complex regulatory and commercial landscapes.

What we're watching

Regulatory Approval: The pace at which AVT34 and AVT87 secure U.S. and Asian regulatory approvals will determine commercialization timelines.
Market Penetration: Whether Alvotech and Lotus can effectively compete against AstraZeneca and Roche in high-value therapeutic areas.
Revenue Realization: How quickly the $150M deal value materializes through upfront payments, milestones, and ongoing supply revenues.